Navidea Biopharmaceuticals Inc. has announced an extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares. The company's Board of Directors will decide on the timing and specific ratio. The move aims to simplify the company's capitalization and reduce the number of record holders to stay below the SEC threshold for public reporting, which involves significant costs. The authorization, originally expiring on July 8, 2025, has been extended to July 8, 2027.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。